Structural features of tumors in patients with neurofibromatosis type 2

V. I. Tsymbalyuk, M. V. Kvasnitskiy, T. A. Malysheva


During 25 years in the clinic 37 patients with neurofibromatosis type 2 (NF2), including 17 men and 20 women were observed. Average age of patients was 23 years. 80 % of patients had been diagnosed bilaterial acoustic neurinoma, for 15 % - unilateral one, at 5 % - multiple tumors of brain and spinal cord. Neurinomas of craniocerebral nerves, except acoustical, were revealed in 8 % of patients, and a neurinomas of spinal nerves - in 11 %. In 33 % of NF2 patients neurinomas were combined with meningiomas, and in 8 — meningiomas were multiple. The surgery material was researched morphologically. On histological structure there were mainly neurinomas (36) and meningiomas (16). Among last — mainly fibroblastic (10) and mixed — fibrobplastic and angiomatose components (4). Neurofibromas occurred only in 4 cases. Some structural features of neurinoma’s structure at NF2 in young patients were revealed: increased fibril formation, attributes of sclerosis and a hyalinosis of vessel wall that predetermines technical difficulties in removing of such tumors and high risk of intraoperative bleeding. In the investigated cases proliferative potential of neurinomas in NF2 patients is low, that is evidence of an opportunity of dynamic observation of young patients with neuro­fibromatosis. Some morphological and proliferative correlations between hypodermic tumors with intracranial and spinal tumors were found.


нейрофіброматоз 2-го типу; акустична невринома; структура


Коршунов А.Г., Шишкина Л.В., Голанов А.В. Пролиферативные маркеры в менингиомах: иммуногистохимическое исследование и анализ прогностической значимости // Арх.патологии. — 2002. — №1. — С.29–33.

Пожарисский К.М., Леенман Е.Е. Значение иммуногистохимических методик для определения характера лечения и прогноза опухолевых заболеваний // Арх. патологии. — 2000. — №5. — С. 3–11.

Руководство по иммуногистохимической диагностике опухолей человека/ Под ред. С. В. Петрова, Н.Т.Райхлина. — Казань, 2000. — 287 с.

Серов В.В., Шехтер А.Б. Соединительная ткань. — М.: Медицина, 1981. — 312 с.

Хоминский Б.С. Опухоли нервной системы // Многотомное руководство по патологической анатомии. — М.: Медгиз, 1962. — Т.2. — 560 с.

Aguiar P.H., Tatagiba M., Samii M. et al. The comparison between the growth fraction of bilateral vestibular schwannomas in neurofibromatosis 2 (NF2) and unilateral vestibular schwannomas using the monoclonal antibody MIB1 //Acta Neurochir.–1995.–V.134.–P.40–45.

Antinheimo J., Haapasalo H., Seppala M. et al. Proliferative po­tential of sporadic and neuro­fibromatosis 2-associated schwannomas as studied by MIB-1 (Ki-67) and PCIMA labeling // J. Neuropathol. Exp. Neurol. — 1995. — N 54. — Р. 776–782.

Evans D.G. Neurofibromatosis type 2: Genetic and clinical features //Ear, Nose & Throat J. — 1999. — V.78, N2. — P.97–100.

Pollack J.M., van Noorden S. Immunocytochemistry. Practical applications in pathology and biology. –Bristol; London; Boston: Wright. PSG, 1983.

Rouleau G.A., Merel P., Lutchman M. et al. Alteration in new gene encoding a putative membrane-organizing protein neurofibromatosis type 2 // Nature. — 1993. — V.363. — Р. 515–521.

Rubenstein A.E., Korf B.R. Neurofibromatosis: A Handbook For Patients, Families, and Health-Care Professionals. — Stuttgart; New York: Georg Thieme Verlag,1990. — 256 р.

Russell D.S., Rubinstein L.J. Pathology of Tumours of the Nervous System. — 5th ed. — London: Edward Arnold,1989. — 180 р.

Trofatter J.A., Mac Collin M.M., Rutter J.L. et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor //Cell. — 1993. — V.72 .– P. 1–20.

Welling D.B. Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas) // Laryngoscope. — 1998. — N 2. — Р. 108.

GOST Style Citations

Copyright (c) 2003 V. I. Tsymbalyuk, M. V. Kvasnitskiy, T. A. Malysheva

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.